ONCY stock forecast, quote, news & analysis
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company... Show more
Why Oncolytics Biotech (ONCY) Stock Is Down -30% in the Last 30 Days
Key Takeaways
- ONCY shares declined roughly 30% over the last 30 days, falling from about $0.66 to around $0.46 per share.
- The pullback extends a longer slide, with the stock down approximately 42% over the last quarter.
- Lake Street Capital Markets attributed the weakness to ongoing dilution concerns and soft small-cap biotech sentiment rather than any change in the company's fundamentals.
- Clinical momentum continued through the period, including updated GOBLET Cohort 4 data, an intellectual property portfolio update, and a colorectal cancer presentation at ESMO 2026.
- Analyst views remain divided, with a Buy rating and $5 price target from Lake Street contrasting with a Sell (D-) rating from Weiss Ratings.
- For more detailed research, visit Tickeron's Price Targets, Earnings, and Forecast pages.
- Explore automated strategies with Tickeron's Trending AI Robots.
Oncolytics Biotech (ONCY) Company Overview and Market Position
Oncolytics Biotech Inc. is a clinical-stage immunotherapy company developing pelareorep, an intravenously delivered, double-stranded RNA immunotherapeutic agent based on a non-genetically modified reovirus. The therapy is designed to selectively replicate in tumor cells while activating both innate and adaptive anti-tumor immune responses, effectively helping convert immunologically "cold" tumors into "hot" ones that are more responsive to checkpoint inhibitors and other cancer treatments.
Pelareorep has been administered to more than 1,200 patients, and the company has reported encouraging data across first-line metastatic pancreatic ductal adenocarcinoma, hormone receptor-positive/HER2-negative metastatic breast cancer, and early-stage anal and colorectal cancers. Investors follow ONCY closely because of its registrational ambitions in gastrointestinal and breast cancers and its potential path toward accelerated approval.
Oncolytics Biotech (ONCY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ONCY declined roughly 30%, moving from a closing price near $0.66 to approximately $0.46. The slide was not linear: shares fell sharply in late September and again in mid-October, with intermittent bounces that did not hold.
The 30-day move is part of a broader multi-month downtrend. Measured against the closing level of about $0.79 from late July, the stock has lost roughly 42% over the last quarter. This longer decline reflects sustained selling pressure across the small-cap biotechnology segment, compounded by company-specific financing concerns.
What Drove ONCY Stock Price in the Last 30 Days
The most visible catalyst cited by analysts was sentiment rather than fundamentals. On October 14, Lake Street analyst Chad Messer reiterated a Buy rating and a $5 price target, noting that shares were testing summer lows and describing the weakness as reflecting "ongoing dilution concerns and soft small-cap biotech sentiment rather than any change in the fundamental story."
Against that backdrop, the company maintained an active news flow. On October 12, Oncolytics announced an intellectual property portfolio update, reporting that a new method-of-use patent covering pelareorep as an immunotherapy had been issued in several countries, with a corresponding U.S. patent expected soon. The company also outlined plans for a potential composition-of-matter patent on a "next generation" pelareorep, extending its existing manufacturing protection through 2044 toward the late 2040s.
On October 14, the company provided a GOBLET study update, indicating that final results from Cohort 4 — evaluating pelareorep with atezolizumab in second-line and later squamous cell anal cancer — are expected in the fourth quarter of 2026, while initial Cohort 5 pancreatic cancer results are anticipated in the first half of 2027. Updated Cohort 4 data followed on October 27. The company also presented a Phase 2 colorectal cancer abstract at ESMO 2026, referencing interactions with the FDA around a potential pivotal expansion.
Not all commentary was positive. On October 9, Weiss Ratings reiterated a Sell (D-) rating on the stock, illustrating the divergence in views surrounding the company's clinical and financing outlook.
What Drove ONCY Stock Performance Over the Last Quarter
Over the last quarter, ONCY's decline has been driven less by clinical setbacks and more by financing and capital structure concerns. As a clinical-stage company with no approved products, Oncolytics relies on periodic capital raises to fund its development programs, and the prospect of equity dilution has weighed on the share price.
At the same time, the broader small-cap biotechnology complex has faced headwinds from risk-averse positioning and reduced investor appetite for pre-revenue names. While the company continued to advance pelareorep across multiple indications and secured patent milestones, these fundamental developments were not enough to offset the persistent selling pressure during the period.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a platform that operates hundreds of AI-driven bots across thousands of tickers. Rather than listing every available bot, the section highlights only the top-performing and most relevant strategies, helping traders and investors filter through the noise. The bots featured vary widely in approach, trading timeframe, and performance metrics, allowing users to explore strategies aligned with different risk profiles and objectives. For investors seeking to complement their research on names like ONCY with systematic, data-driven tools, reviewing the Trending AI Robots section can provide a useful starting point.
ONCY Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for ONCY are clinical and regulatory. Investors are likely to focus on the final results from GOBLET Cohort 4 in anal cancer, expected in the fourth quarter of 2026, and on initial data from Cohort 5 in first-line metastatic pancreatic cancer, anticipated in the first half of 2027. The potential U.S. issuance of the pelareorep method-of-use patent and progress toward the "next generation" pelareorep composition-of-matter filing are additional milestones to monitor.
Financing remains a key risk. As a pre-revenue biotech, the company's ability to fund registrational trials without excessive dilution will be central to investor sentiment. Broader macroeconomic conditions, sector rotation into or out of small-cap biotechnology, and analyst expectations will also shape the stock's direction. As always, these factors carry uncertainty, and investors should conduct their own due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ONCY in -13.11% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONCY declined for three days, in 290 of 332 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ONCY entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ONCY's RSI Indicator exited the oversold zone, 39 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ONCY just turned positive on November 04, 2026. Looking at past instances where ONCY's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
Following a +15.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCY advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ONCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.085) is normal, around the industry mean (3.498). P/E Ratio (-1.255) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products for the treatment of cancers
Industry Biotechnology